ATAI Life Sciences

Yahoo Finance • 18 days ago

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts

AtaiBeckley awarded ‘Buy’ rating in initial coverage from Deutsche Bank analysts Proactive uses images sourced from Shutterstock Deutsche Bank has initiated coverage on AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) assigning a 'Buy' rating an... Full story

Yahoo Finance • 21 days ago

AtaiBeckley added to major US indices, increasing reach among passive investors

AtaiBeckley added to major US indices, increasing reach among passive investors Proactive uses images sourced from Shutterstock AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced that it has been added to a series of major US equity benc... Full story

Yahoo Finance • 28 days ago

BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenie... Full story

Yahoo Finance • last month

AtaiBeckley Advances BPL-003 Into Phase 3 For Treatment-Resistant Depression

(RTTNews) - AtaiBeckley Inc. (ATAI) is moving forward with its pivotal Phase 3 program for BPL-003, a nasal spray therapy designed for patients with treatment-resistant depression (TRD). The company confirmed the program is on track to beg... Full story

Yahoo Finance • last month

AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best new penny stocks to buy. On March 6, AtaiBeckley reported full-year 2025 earnings, which were highlighted by the pivotal execution phase following the strategic combination of Atai Life Sci... Full story

Yahoo Finance • last month

AtaiBeckley weighing options for lead psychedelic therapy: Bloomberg

[The arrow hit the highlighted yellow target.] Andrii Yalanskyi AtaiBeckley (ATAI [https://seekingalpha.com/symbol/ATAI]) is in talks with advisors to explore strategic options for BPL-003, its lead psychedelic drug candidate, seeking at... Full story

Yahoo Finance • last month

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01 Phase 2 Elumina trial t... Full story

Yahoo Finance • last month

AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best low cost stocks to buy under $5. On March 3, AtaiBeckley announced a successful End-of-Phase 2 meeting with the FDA regarding BPL-003, a proprietary intranasal formulation of mebufotenin be... Full story

Yahoo Finance • last month

AtaiBeckley Inc (ATAI)’s Drug Candidate EMP-01 Shows Positive Results in Key Study

AtaiBeckley Inc (NASDAQ:ATAI) is among the 13 best NASDAQ penny stocks to buy according to analysts. On February 26, AtaiBeckley Inc (NASDAQ:ATAI) reported topline results from a Phase 2a trial of its drug candidate EMP-01 (oral R-MDMA), w... Full story

Yahoo Finance • 2 months ago

AtaiBeckley names Michael Faerm as finance chief

AtaiBeckley names Michael Faerm as finance chief Proactive uses images sourced from Shutterstock AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as... Full story

Yahoo Finance • 2 months ago

Here’s What Analysts Are Saying About AtaiBeckley Inc. (ATAI)

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best strong buy penny stocks to invest in. AtaiBeckley Inc. (NASDAQ:ATAI) has received several rating updates since the beginning of the year. H.C. Wainwright expressed bullish sentiments for At... Full story

Yahoo Finance • 3 months ago

AtaiBeckley Completes Redomiciliation to the United States

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and con... Full story

Yahoo Finance • 4 months ago

Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy fr... Full story

Yahoo Finance • 4 months ago

AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)

AtaiBeckley N.V. NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing... Full story

Yahoo Finance • 5 months ago

H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion

Atai Beckley NV (NASDAQ:ATAI) ranks among the most oversold biotech stocks to invest in. H.C. Wainwright reaffirmed its Buy rating and $15 price target for Atai Beckley NV (NASDAQ:ATAI) on November 14 following the company’s third-quarter... Full story

Yahoo Finance • 5 months ago

Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato

Atai Beckley NV (NASDAQ:ATAI) is a must-buy penny stock to buy now. On November 12, TD Cowen’s Ritu Baral reaffirmed a Buy rating on Atai Beckley NV (NASDAQ:ATAI), pointing to encouraging clinical progress and solid financial footing. Posi... Full story

Yahoo Finance • 5 months ago

ATAI Life Sciences GAAP EPS of -$0.28 misses by $0.17, revenue of $0.75M beats by $0.69M

* ATAI Life Sciences press release [https://seekingalpha.com/pr/20303399-ataibeckley-reports-third-quarter-2025-financial-results-and-recent-corporate-highlights] (ATAI [https://seekingalpha.com/symbol/ATAI]): Q3 GAAP EPS of -$0.28 misse... Full story

Yahoo Finance • 5 months ago

AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b open-label extensi... Full story

Yahoo Finance • 6 months ago

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on O... Full story

Yahoo Finance • 6 months ago

Cathie Wood's Ark Invest weekly recap: buys BABA, BIDU; sheds PLTR, SHOP and SOFI

Cathie Wood’s ARK ETFs have made several significant trades during the last week, adjusting their portfolios across various sectors. TOP STOCKS BOUGHT: Ark Funds continues to build a position in Alibaba (BABA [https://seekingalpha.com/sy... Full story